INDIANAPOLIS and SAN FRANCISCO , July 16, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock to the public at $36.00 per share, which included

INDIANAPOLIS and SAN FRANCISCO , July 11, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock to the public at $36.00 per share.

INDIANAPOLIS and SAN FRANCISCO , July 10, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced that it intends to offer and sell, subject to market and other conditions, 3,000,000 shares of its common stock in an underwritten public offering.

Key aim is to demonstrate that core inhibitor therapy combined with standard of care antivirals can offer curative potential for HBV INDIANAPOLIS and SAN FRANCISCO, July 09, 2018 (GLOBE NEWSWIRE) --   Assembly Biosciences, Inc.  (Nasdaq:ASMB), today announced the initiation of two multi-center,

Live event and webcast to focus on the potential of curative therapy for HBV infection and feature presentations from two liver medicine specialists INDIANAPOLIS and SAN FRANCISCO, June 13, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences , Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company

INDIANAPOLIS and SAN FRANCISCO , June 08, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral synthetic live biotherapeutics for

INDIANAPOLIS and SAN FRANCISCO , June 04, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral synthetic live biotherapeutics for

INDIANAPOLIS and SAN FRANCISCO , May 07, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral synthetic live biotherapeutics for

Robust antiviral activity observed in HBV patients Generally safe and well tolerated Planning underway for Phase 2a studies beginning summer 2018 Company to host conference call on Thursday, April 12 th at 8am ET / 2pm CEST INDIANAPOLIS and SAN FRANCISCO , April 12, 2018 (GLOBE NEWSWIRE) --

INDIANAPOLIS and SAN FRANCISCO , April 10, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders